<p>Changing Ivermectin Information after much mockery.</p>

<div dir="ltr">
  

  
    Affiliations
  

  
    <button data-alt-text="Collapse" aria-controls="expanded-authors" aria-expanded="false" data-pinger-ignore="" data-fetch-url="/35070575/long-authors/" data-id-prefix="" dir="ltr">
      <span dir="ltr">
        Expand
      </span>
    </button>
  
</div><div dir="ltr">
  


        
  <span dir="ltr">Free PMC article</span>

        
      </div><UL><LI><div><span>Kerr L, Cadegiani FA, Baldi F, Lobo RB, Assagra WLO, Proença FC, Kory P, Hibberd JA, Chamie-Quintero JJ.</span></div><div><span>Cureus. 2022 Mar 24;14(3):c61. doi: 10.7759/cureus.c61. eCollection 2022 Mar.</span></div><div dir="ltr">
    
  
  <span dir="ltr">PMID: <span dir="ltr">35371877</span></span>
  <span dir="ltr">Free PMC article.</span>
  
  
  
  
</div></LI></UL><h2>
        Abstract
        
      </h2><p dir="ltr">
      
        <strong dir="ltr">
          Background:
        </strong>
      
      Ivermectin has demonstrated different mechanisms of action that potentially protect from both coronavirus disease 2019 (COVID-19) infection and COVID-19-related comorbidities. Based on the studies suggesting efficacy in prophylaxis combined with the known safety profile of ivermectin, a citywide prevention program using ivermectin for COVID-19 was implemented in Itajaí, a southern city in Brazil in the state of Santa Catarina. The objective of this study was to evaluate the impact of regular ivermectin use on subsequent COVID-19 infection and mortality rates.
    </p><p dir="ltr">
      
        <strong dir="ltr">
          Materials and methods:
        </strong>
      
      We analyzed data from a prospective, observational study of the citywide COVID-19 prevention with ivermectin program, which was conducted between July 2020 and December 2020 in Itajaí, Brazil. Study design, institutional review board approval, and analysis of registry data occurred after completion of the program. The program consisted of inviting the entire population of Itajaí to a medical visit to enroll in the program and to compile baseline, personal, demographic, and medical information. In the absence of contraindications, ivermectin was offered as an optional treatment to be taken for two consecutive days every 15 days at a dose of 0.2 mg/kg/day. In cases where a participating citizen of Itajaí became ill with COVID-19, they were recommended not to use ivermectin or any other medication in early outpatient treatment. Clinical outcomes of infection, hospitalization, and death were automatically reported and entered into the registry in real time. Study analysis consisted of comparing ivermectin users with non-users using cohorts of infected patients propensity score-matched by age, sex, and comorbidities. COVID-19 infection and mortality rates were analyzed with and without the use of propensity score matching (PSM).
    </p><p dir="ltr">
      
        <strong dir="ltr">
          Results:
        </strong>
      
      Of the 223,128 citizens of Itajaí considered for the study, a total of 159,561 subjects were included in the analysis: 113,845 (71.3%) regular ivermectin users and 45,716 (23.3%) non-users. Of these, 4,311 ivermectin users were infected, among which 4,197 were from the city of Itajaí (3.7% infection rate), and 3,034 non-users (from Itajaí) were infected (6.6% infection rate), with a 44% reduction in COVID-19 infection rate (risk ratio [RR], 0.56; 95% confidence interval (95% CI), 0.53-0.58; p &lt; 0.0001). Using PSM, two cohorts of 3,034 subjects suffering from COVID-19 infection were compared. The regular use of ivermectin led to a 68% reduction in COVID-19 mortality (25 [0.8%] versus 79 [2.6%] among ivermectin non-users; RR, 0.32; 95% CI, 0.20-0.49; p &lt; 0.0001). When adjusted for residual variables, reduction in mortality rate was 70% (RR, 0.30; 95% CI, 0.19-0.46; p &lt; 0.0001). There was a 56% reduction in hospitalization rate (44 versus 99 hospitalizations among ivermectin users and non-users, respectively; RR, 0.44; 95% CI, 0.31-0.63; p &lt; 0.0001). After adjustment for residual variables, reduction in hospitalization rate was 67% (RR, 0.33; 95% CI, 023-0.66; p &lt; 0.0001).
    </p><p dir="ltr">
      
        <strong dir="ltr">
          Conclusion:
        </strong>
      
      In this large PSM study, regular use of ivermectin as a prophylactic agent was associated with significantly reduced COVID-19 infection, hospitalization, and mortality rates.
    </p><p dir="ltr">
      
        <strong dir="ltr">
          Keywords:
        </strong>
      
      coronavirus; covid-19; ivermectin; prevention; prophylaxis; sars-cov-2.
    </p><p>
    Copyright © 2022, Kerr et al.
  </p><h3>
      Conflict of interest statement
    </h3><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The authors have declared that no competing interests exist.</p><figure><img src="https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8765582/bin/cureus-0014-00000021272-i01.gif" alt="Figure 1" width="75" height="18"><figcaption dir="auto">
                  
                  



  
    
      Figure 1. Underlying data for the study on ivermectin prophylaxis used for COVID-19.
    
  

  



                </figcaption></figure><UL><LI><div><span>Popp M, Stegemann M, Metzendorf MI, Gould S, Kranke P, Meybohm P, Skoetz N, Weibel S.</span></div><div><span>Cochrane Database Syst Rev. 2021 Jul 28;7(7):CD015017. doi: 10.1002/14651858.CD015017.pub2.</span></div><div dir="ltr">
    
  
  <span dir="ltr">PMID: <span dir="ltr">34318930</span></span>
  <span dir="ltr">Free PMC article.</span>
  <span dir="ltr">Updated.</span>
  
  
  
</div></LI><LI><div><span>Vallejos J, Zoni R, Bangher M, Villamandos S, Bobadilla A, Plano F, Campias C, Chaparro Campias E, Achinelli F, Guglielmone HA, Ojeda J, Medina F, Farizano Salazar D, Andino G, Ruiz Diaz NE, Kawerin P, Meza E, Dellamea S, Aquino A, Flores V, Martemucci CN, Vernengo MM, Martinez SM, Segovia JE, Aguirre MG.</span></div><div><span>Trials. 2020 Nov 24;21(1):965. doi: 10.1186/s13063-020-04813-1.</span></div><div dir="ltr">
    
  
  <span dir="ltr">PMID: <span dir="ltr">33234158</span></span>
  <span dir="ltr">Free PMC article.</span>
  
  <span dir="ltr">Clinical Trial.</span>
  
  
</div></LI><LI><div><span>Morgenstern J, Redondo JN, Olavarria A, Rondon I, Roca S, De Leon A, Canela J, Tavares J, Minaya M, Lopez O, Castillo A, Placido A, Cruz R, Merette Y, Toribio M, Francisco J.</span></div><div><span>Cureus. 2021 Aug 26;13(8):e17455. doi: 10.7759/cureus.17455. eCollection 2021 Aug.</span></div><div dir="ltr">
    
  
  <span dir="ltr">PMID: <span dir="ltr">34513523</span></span>
  <span dir="ltr">Free PMC article.</span>
  
  
  
  
</div></LI><LI><div><span>Harmer B, Lee S, Duong TVH, Saadabadi A.</span></div><div><span>2022 May 18. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–.</span></div><div dir="ltr">
    
  
  <span dir="ltr">PMID: <span dir="ltr">33351435</span></span>
  <span dir="ltr">Free Books &amp; Documents.</span>
  
  
  
  
</div></LI><LI><div><span>Haran JP, Pinero JC, Zheng Y, Palma NA, Wingertzahn M.</span></div><div><span>Trials. 2021 Apr 2;22(1):245. doi: 10.1186/s13063-021-05157-0.</span></div><div dir="ltr">
    
  
  <span dir="ltr">PMID: <span dir="ltr">33810796</span></span>
  <span dir="ltr">Free PMC article.</span>
  
  
  
  
</div></LI></UL><div dir="ltr">
  
  
    <a data-href="/?linkname=pubmed_pubmed&amp;from_uid=35070575" data-ga-category="similar_article" data-ga-action="show_all" dir="ltr">
      See all similar articles
    </a>
  
</div><UL><LI><div><span>Hazan S.</span></div><div><span>Front Microbiol. 2022 Jul 11;13:952321. doi: 10.3389/fmicb.2022.952321. eCollection 2022.</span></div><div dir="ltr">
    
  
  <span dir="ltr">PMID: <span dir="ltr">35898916</span></span>
  <span dir="ltr">Free PMC article.</span>
  
  
  
  
</div></LI></UL>

The current way Americans interact with the news and the way the media presents stories is a grave concern, as it's treated more as a major league football grudge match than it is seeking and reporting truth.

In this large PSM study, regular use of ivermectin as a prophylactic agent was associated with significantly reduced COVID-19 infection, hospitalization, and mortality rates.

<ul><li><div><span>Kerr L, Cadegiani FA, Baldi F, Lobo RB, Assagra WLO, Proença FC, Kory P, Hibberd JA, Chamie-Quintero JJ. </span> </div><div><span>Cureus. 2022 Mar 24;14(3):c61. doi: 10.7759/cureus.c61. eCollection 2022 Mar. </span> </div><div><span>PMID: <span>35371877 </span> </span><span>Free PMC article. </span> </div> </li> </ul>

<p><strong>Background: </strong>Ivermectin has demonstrated different mechanisms of action that potentially protect from both coronavirus disease 2019 (COVID-19) infection and COVID-19-related comorbidities. Based on the studies suggesting efficacy in prophylaxis combined with the known safety profile of ivermectin, a citywide prevention program using ivermectin for COVID-19 was implemented in Itajaí, a southern city in Brazil in the state of Santa Catarina. The objective of this study was to evaluate the impact of regular ivermectin use on subsequent COVID-19 infection and mortality rates. </p>

<p><strong>Materials and methods: </strong>We analyzed data from a prospective, observational study of the citywide COVID-19 prevention with ivermectin program, which was conducted between July 2020 and December 2020 in Itajaí, Brazil. Study design, institutional review board approval, and analysis of registry data occurred after completion of the program. The program consisted of inviting the entire population of Itajaí to a medical visit to enroll in the program and to compile baseline, personal, demographic, and medical information. In the absence of contraindications, ivermectin was offered as an optional treatment to be taken for two consecutive days every 15 days at a dose of 0.2 mg/kg/day. In cases where a participating citizen of Itajaí became ill with COVID-19, they were recommended not to use ivermectin or any other medication in early outpatient treatment. Clinical outcomes of infection, hospitalization, and death were automatically reported and entered into the registry in real time. Study analysis consisted of comparing ivermectin users with non-users using cohorts of infected patients propensity score-matched by age, sex, and comorbidities. COVID-19 infection and mortality rates were analyzed with and without the use of propensity score matching (PSM). </p>

<p><strong>Results: </strong>Of the 223,128 citizens of Itajaí considered for the study, a total of 159,561 subjects were included in the analysis: 113,845 (71.3%) regular ivermectin users and 45,716 (23.3%) non-users. Of these, 4,311 ivermectin users were infected, among which 4,197 were from the city of Itajaí (3.7% infection rate), and 3,034 non-users (from Itajaí) were infected (6.6% infection rate), with a 44% reduction in COVID-19 infection rate (risk ratio [RR], 0.56; 95% confidence interval (95% CI), 0.53-0.58; p < 0.0001). Using PSM, two cohorts of 3,034 subjects suffering from COVID-19 infection were compared. The regular use of ivermectin led to a 68% reduction in COVID-19 mortality (25 [0.8%] versus 79 [2.6%] among ivermectin non-users; RR, 0.32; 95% CI, 0.20-0.49; p < 0.0001). When adjusted for residual variables, reduction in mortality rate was 70% (RR, 0.30; 95% CI, 0.19-0.46; p < 0.0001). There was a 56% reduction in hospitalization rate (44 versus 99 hospitalizations among ivermectin users and non-users, respectively; RR, 0.44; 95% CI, 0.31-0.63; p < 0.0001). After adjustment for residual variables, reduction in hospitalization rate was 67% (RR, 0.33; 95% CI, 023-0.66; p < 0.0001). </p>

<p><strong>Conclusion: </strong>In this large PSM study, regular use of ivermectin as a prophylactic agent was associated with significantly reduced COVID-19 infection, hospitalization, and mortality rates. </p>

<p><strong>Keywords: </strong>coronavirus; covid-19; ivermectin; prevention; prophylaxis; sars-cov-2. </p>

<p>The authors have declared that no competing interests exist. </p>

<ul><li><div><span>Popp M, Stegemann M, Metzendorf MI, Gould S, Kranke P, Meybohm P, Skoetz N, Weibel S. </span> </div><div><span>Cochrane Database Syst Rev. 2021 Jul 28;7(7):CD015017. doi: 10.1002/14651858.CD015017.pub2. </span> </div><div><span>PMID: <span>34318930 </span> </span><span>Free PMC article. </span><span>Updated. </span> </div> </li><li><div><span>Vallejos J, Zoni R, Bangher M, Villamandos S, Bobadilla A, Plano F, Campias C, Chaparro Campias E, Achinelli F, Guglielmone HA, Ojeda J, Medina F, Farizano Salazar D, Andino G, Ruiz Diaz NE, Kawerin P, Meza E, Dellamea S, Aquino A, Flores V, Martemucci CN, Vernengo MM, Martinez SM, Segovia JE, Aguirre MG. </span> </div><div><span>Trials. 2020 Nov 24;21(1):965. doi: 10.1186/s13063-020-04813-1. </span> </div><div><span>PMID: <span>33234158 </span> </span><span>Free PMC article. </span><span>Clinical Trial. </span> </div> </li><li><div><span>Morgenstern J, Redondo JN, Olavarria A, Rondon I, Roca S, De Leon A, Canela J, Tavares J, Minaya M, Lopez O, Castillo A, Placido A, Cruz R, Merette Y, Toribio M, Francisco J. </span> </div><div><span>Cureus. 2021 Aug 26;13(8):e17455. doi: 10.7759/cureus.17455. eCollection 2021 Aug. </span> </div><div><span>PMID: <span>34513523 </span> </span><span>Free PMC article. </span> </div> </li><li><div><span>Harmer B, Lee S, Duong TVH, Saadabadi A. </span> </div><div><span>2022 May 18. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. </span> </div><div><span>PMID: <span>33351435 </span> </span><span>Free Books & Documents. </span> </div> </li><li><div><span>Haran JP, Pinero JC, Zheng Y, Palma NA, Wingertzahn M. </span> </div><div><span>Trials. 2021 Apr 2;22(1):245. doi: 10.1186/s13063-021-05157-0. </span> </div><div><span>PMID: <span>33810796 </span> </span><span>Free PMC article. </span> </div> </li> </ul>

<ul><li><div><span>Hazan S. </span> </div><div><span>Front Microbiol. 2022 Jul 11;13:952321. doi: 10.3389/fmicb.2022.952321. eCollection 2022. </span> </div><div><span>PMID: <span>35898916 </span> </span><span>Free PMC article. </span> </div> </li> </ul>

Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching - PubMed

CURATED BY

CURATOR'S NOTE

More like this